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HCV infection is a cause and complication of kidney disease, both chronic [12] and acute [13] . On the one hand, HCV can cause glomerular disease and worsen outcomes in dialysis and kidney transplantation. On the other hand, patients on dialysis are at high risk of HCV infection. Evidence regarding the burden and treatment of HCV in kidney disease patients is rather limited, and the majority of recommendations in the international guideline that focus on HCV in kidney patients [14] are regarded as having weak level of strength. Importantly, several recent papers have highlighted different aspects of the interplay between HCV and chronic kidney disease. In this issue of Nephron , Solid et al. [15] analyzed outcomes, healthcare utilization, and health encounter-related costs (excluding pharmacy costs) for 2 large US administrative claims databases. They found the prevalence of CKD or ESKD among HCV-positive persons to be 8.5% for patients aged 20-64 years (MarketScan cohort), and 26.5% for patients aged 65 years or older (Medicare cohort) -these numbers are somewhat lower than the CKD prevalence in the general population according to NHANES [16] , which reported that CKD prevalence is The hepatitis C virus (HCV) is a global health threat. The available data suggest that HCV prevalence is at about 2-3% of the world's population (130-170 million people) [1] , and in 2013 alone, almost 700,000 deaths were directly attributed to HCV [2] . In spite of this tremendous burden, globally less than 1% of people with a chronic hepatitis infection were receiving treatment [3] , and HCV is one of the few communicable disorders that continue to grow, with a 47% increase in mortality over the last 2 decades [2] . The majority of HCV-infected individuals are unaware of their infection [4] , and screening for HCV was not recommended until recently. This may facilitate the spread of HCV not only in high-risk groups, but also in populations with low HCV prevalence affected by the recent humanitarian crisis with mass migration from regions with higher HCV rates. In May 2016, the World Health Organization adopted the first-ever global strategy to reduce the incidence of all viral hepatitis by 90% and mortality by 65% by 2030 [3, 5] , which requires both the prevention of HCV transmission in high-risk groups and effective treatment for individuals already infected. The recent availability of direct-acting antiviral drugs (DAAs), with a 80-97% efficacy rate regarding sustainable HCV RNA clearance and fewer side effects compared with previous treatment options [6] [7] [8] [9] [10] [11] provided hope for a successful cure. But even in patients who are aware of their own HCV infection, there are substantial 32.6% among persons aged 60 years or older. This discrepancy could be attributed partially to differences in age, sex, and other case-mix parameters between participants of the analysis performed by Solid et al. [15] and the NHANES, but would require further explanation from the authors. Patients with HCV and kidney disease were found to have higher healthcare utilization, almost across the board (inpatient hospitalizations, outpatient claims), as well as higher medical costs, and total mortality rates [15, 17] . Notably, for these patients healthcare utilization increased significantly for cardiovascular and infection events [15] and was not limited to hepatitis-related causes [17] . Moreover, compared with HCV-infected patients without kidney disease, those with CKD had more than 70%, and with ESRD more than 150% higher all-cause medical costs in adjusted analysis [15] . In absolute numbers, the all-cause medical cost per HCV-infected member per month was about 1,000 USD for patients without kidney disease, about 3,000 USD for patients with CKD, and almost 8,000 USD for ESRD patients in both the MarketScan and Medicare cohorts. HCV-related medical costs vary substantially between cohorts, amounting to 279 USD for patients without kidney disease, 978 USD for patients with CKD, and 1,715 USD for ESRD patients in the MarketScan cohort, and to only 96, 228, and 107 USD, respectively, in the Medicare cohort. Such low numbers are in line with the finding that only 1.5% of hemodialysis HCV-infected patients received antiviral treatment in the international DOPPS analysis [17] . These findings need further explanation, but could be attributed to unrecognized HCV liver damage due to normal or only slightly elevated liver enzymes [12] , especially in ESRD patients [17] . Together, these data could provide important input for the cost-effectiveness analysis focused on HCV treatment in CKD patients. Even in the general population, the cost of antiviral treatment is exceptionally high. For example, in the USA the cost for 12 weeks of treatment per patient, for different DAAs regimens, ranges between 55,000 and 150,000 USD regarding wholesale acquisition prices [18] and reaches a median cost of 113,400 USD in a real-world analysis [8] . However, several analyses conducted in the USA [19, 20] have assumed that DAA treatment is cost-effective, especially in patients with less prominent liver fibrosis. But the high cost of therapy limits reimbursement for drugs only to advanced liver disease and to patients with transplanted organs in the USA [8] and some countries in Western Europe [6] . Moreover, the rate of sustainable viral response varies depending on the applied DAAs schedule, HCV genotype, the extent of liver fibrosis, kidney dysfunction, prior treatment history, and other factors [6, 8, 10] . In addition, the threshold for cost-effectiveness varies for countries with different levels of economic development, which is a further hurdle to providing DAAs. However, expenses could be negotiated and lowered if there were increased market competition or a single source mass purchase. For example, the Egyptian government negotiated a DAA price that was almost 100 times lower than the US wholesale price [18] .
Several other hurdles, in addition to a lack of awareness and the extremely high costs of antiviral treatment, could further limit our ability to combat HCV. Specifically, DAA therapy has significant implications for kidney disease patients. Sofosbuvir, the principal component of most modern treatment strategies, and its active metabolites, are mainly eliminated by the kidney, which increases the risk of accumulation. It is also removed by hemodialysis, which could lead to insufficient therapeutic concentration. These features require the appropriate protocols for drug dosage and probably plasma drug monitoring [21] , although the evidence regarding small groups of CKD patients suggests good tolerability and HCV eradication [9, 21, 22] . There could also be interactions between immunosuppressive drugs and DAAs [22] . Currently, ongoing phase 2 or phase 3 clinical trials that include patients with kidney impairment [9] , and the results of longitudinal observational surveys [10] , should provide further evidence regarding the safety and efficacy of anti-HCV therapy.
Some precautions are also taken when treating patients with a HCV and hepatitis B virus (HBV) co-infection. The co-infection prevalence in the USA revealed by Solid et al. [15] is 1.5-3.0% in the HCV-only population, and 3.7-11.3% in HCV with kidney involvement population (that is close to about a 10% co-infection prevalence in the general global population [18] ). It is noteworthy, that this substantial proportion of patients has an increased risk not only of more rapid liver disease progression, but also of HBV reactivation in case of anti-HCV treatment [23, 24] , which requires strict monitoring throughout therapy.
Several other major obstacles need to be resolved to halt HCV both in the general population and in kidney disease patients. Most importantly, regarding prevention, a HCV vaccine should be developed, since even successfully treated patients can currently be re-infected. Much more work should be put into neglected populations in order to prevent HCV transmission, including universal screening of prisoners [25] and other high-risk groups, needle-exchange programs for people who inject drugs, etc. Diagnostic facilities in low-and middle- income countries have to be enhanced so that the HCV genotype and quantitative HCV RNA, which are essential both for choosing the optimal therapy and monitoring follow-up, can be determined. More therapeutic options for HCV treatment should be introduced, including those that apply to innate immunity mechanisms for natural HCV eradication. All these hurdles warrant further research and worldwide public health action in order to achieve the ambitious goal of eradicating viral hepatitis [3, 5] .
